Grant: Discovery Grants Program - Individual
University of Toronto
$56,000.00
A systematic approach combining process optimization and clinically-relevant quality attributes to manufacture high potency mesenchymal stromal cells for clinical and veterinary applications
FY 2022-23
Summary
Problem Although advances in bioreactor technology allow for scalable manufacturing of mesenchymal stromal cells (MSCs), many of these methods are borrowed from the vaccine and antibody industry, and do not prioritize cell functionality. Commercial-scale expansion of MSCs contributed to sub-optimal performance in late-phase trials for multiple companies. Enhanced manufacturing methods that produce scaleable and fuctional MSCs are needed to capitalize on the substantial investment in MSCs. Solution My lab has filed a patent to manufacture scalable 3D MSCs with enhanced anti-inflammatory properties. Using a statistically-based approach, we will systematically optimize bioprocess parameters to manufacture sufficient quantities and quality of therapeutically-relevant MSCs with enhanced anti-inflammatory properties, without increasing costs. First, using iterative Design of Experiment (DoE) and high throughput read-outs, combinations of bioprocess parameters will be modeled and tested for their relative impact on MSC yield, anti-inflammatory factors and cost. Additional processing parameters that affect the metabolic profile of the MSC cultures will be investigated and queried to further optimize combination of bioprocess parameters. Human and canine MSCs will be manufactured in large scales, and tested in domestic dogs with inflammatory disease to validate this approach to optimize bioprocess parameters. O1 Statistical modeling to optimize process parameters that simultaneously improve MSC yield and anti-inflammatory attributes Herein, we use Definitive Screening Designs (DSD) to model the effects of various permutations of bioprocess parameters on MSC yield, potency and calculated cost. A response surface map allows hierarchical clustering of combination of bioprocess parameters that maximize cell yield and potency at low costs. O2 Assess metabolic parameters read-outs to further optimize MSC bioprocess parameters Optimizing metabolic parameters and changes in MSC size and cellular structures will be conducted in this objective using Raman spectroscopy. These parameters can subsequently be monitored on-line in MSC manufacturing vessels providing feedback to rapidly “correct” process parameters in situ.O3 Validate scalability and therapeutic potency of MSCs in veterinary applications Human and canine MSCs will be manufactured in 1L scales using the optimized combination of bioprocess parameters. Canine AT-MSCs will be tested in domestic dogs with joint diseases.Significance The process optimization will result in large scale manufacturing of therapeutically-potent MSCs for effective clinical and veterinary applications in inflammatory diseases. This program offers training opportunities in statistical modeling, bioprocess optimization, cell manufacturing, and veterinary application for HQPs.
Program
Discovery Grants Program - Individual
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
RGPIN-2018-05737
Name nom
Viswanathan, Sowmya
Department département
Biomaterials and Biomedical Engineering, Inst. of (IBBME) - Biomaterials and Biomedical Engineering, Inst. of (IBBME)
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2018
Award amount
56000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1511
Committee name en
Materials and Chemical Engineering
Committee name fr
Génie chimique et des matériaux
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1700
Research subject group en
Design and manufacturing
Research subject group fr
Conception et fabrication
Research subject en
Design and manufacturing
Research subject fr
Conception et fabrication
Installment
inst:5;6
Partie
2
Nb partie
6
Application title
A systematic approach combining process optimization and clinically-relevant quality attributes to manufacture high potency mesenchymal stromal cells for clinical and veterinary applications
Application summary
Problem Although advances in bioreactor technology allow for scalable manufacturing of mesenchymal stromal cells (MSCs), many of these methods are borrowed from the vaccine and antibody industry, and do not prioritize cell functionality. Commercial-scale expansion of MSCs contributed to sub-optimal performance in late-phase trials for multiple companies. Enhanced manufacturing methods that produce scaleable and fuctional MSCs are needed to capitalize on the substantial investment in MSCs. Solution My lab has filed a patent to manufacture scalable 3D MSCs with enhanced anti-inflammatory properties. Using a statistically-based approach, we will systematically optimize bioprocess parameters to manufacture sufficient quantities and quality of therapeutically-relevant MSCs with enhanced anti-inflammatory properties, without increasing costs. First, using iterative Design of Experiment (DoE) and high throughput read-outs, combinations of bioprocess parameters will be modeled and tested for their relative impact on MSC yield, anti-inflammatory factors and cost. Additional processing parameters that affect the metabolic profile of the MSC cultures will be investigated and queried to further optimize combination of bioprocess parameters. Human and canine MSCs will be manufactured in large scales, and tested in domestic dogs with inflammatory disease to validate this approach to optimize bioprocess parameters. O1 Statistical modeling to optimize process parameters that simultaneously improve MSC yield and anti-inflammatory attributes Herein, we use Definitive Screening Designs (DSD) to model the effects of various permutations of bioprocess parameters on MSC yield, potency and calculated cost. A response surface map allows hierarchical clustering of combination of bioprocess parameters that maximize cell yield and potency at low costs. O2 Assess metabolic parameters read-outs to further optimize MSC bioprocess parameters Optimizing metabolic parameters and changes in MSC size and cellular structures will be conducted in this objective using Raman spectroscopy. These parameters can subsequently be monitored on-line in MSC manufacturing vessels providing feedback to rapidly “correct” process parameters in situ.O3 Validate scalability and therapeutic potency of MSCs in veterinary applications Human and canine MSCs will be manufactured in 1L scales using the optimized combination of bioprocess parameters. Canine AT-MSCs will be tested in domestic dogs with joint diseases.Significance The process optimization will result in large scale manufacturing of therapeutically-potent MSCs for effective clinical and veterinary applications in inflammatory diseases. This program offers training opportunities in statistical modeling, bioprocess optimization, cell manufacturing, and veterinary application for HQPs.